Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Autologous TSA-T lymphocytes |
| Synonyms | |
| Therapy Description |
Autologous TSA-T lymphocytes are T-lymphocytes that have been primed with patient tumor-derived neoantigen peptides, which potentially target tumor cells and induce tumor cell lysis (PMID: 34795224). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Autologous TSA-T lymphocytes | Autologous TSA-T lymphocytes are T-lymphocytes that have been primed with patient tumor-derived neoantigen peptides, which potentially target tumor cells and induce tumor cell lysis (PMID: 34795224). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06193759 | Phase I | Autologous TSA-T lymphocytes | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (IMPACT) | Recruiting | USA | 0 |